

To,
The General Manager
BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
14th Floor, Dalal Street,
Fort, Mumbai- 400 001
Scrip Code: 524731.

Reference: Buyback of equity shares of Jenburkt Pharmaceuticals Limited ("Company") from the open market through BSE Limited in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018 ("Buyback Regulations").

Subject : Submission of details of second lot of extinguishment of shares bought back pursuant to provisions of Regulation 21 read with Regulation 11 of the Buyback Regulations.

Dear Sir/ Madam,

Pursuant to the Public Announcement dated 03rd December, 2022 published on 05th December, 2022, the Company commenced buyback of equity shares of face value of Rs. 10/- each fully paid-up (the "Equity Shares") from its shareholders starting from 13th December, 2022.

In accordance with the provisions of Regulation 24(iv) of the Buyback Regulations, this is to inform that the Company has completed the second lot of extinguishment of 8830 (Eight Thousand Eight Hundred Thirty) equity shares bought back under the Buy-back during the period from 23rd December, 2022 to 05th January, 2023. In connection with the same, we are submitting herewith details of second lot of extinguishment of shares along with the debit confirmation letter received from the Central Depository Services Limited as **Annexure A** for your records. The Reconciliation of Share Capital of the Company (Pre and Post extinguishment) is as under:

Reconciliation of Share Capital of the Company (Pre and Post extinguishment) as on 10/01/2023			
Sr. No.	Particulars	No. of shares	Share Capital (in ₹)
1	Paid up Equity shares capital (Prior to buyback)	4589378	45893780
2	Equity Shares extinguished on 10 th January, 2023.	(8830)	(88300)
3	Cumulative Equity Shares Extinguished till date	(32466)	(324660)
4	Shares being extinguished *	Nil	Nil
5	Paid up share capital (Post Extinguishment)	4556912	45569120

- The Company has not initiated process of extinguishment of equity shares bought back after 05th January, 2023.

We confirm that above Equity Shares of the Company were extinguished in compliance with the provisions of Regulation 21 read with Regulation 11 of the Buy-back Regulations.

For Jenburkt Pharmaceuticals Limited,

Ashish R Shah

Company Secretary and Compliance Officer.



CDSL/OPS/IPO-CA/2022-23/CA-504007.002

January 11 , 2023

**The Company Secretary,
Jenburkt Pharmaceuticals Limited**
Nirmala Apartments
93, Jayprakash Road
Andheri West Mumbai, Maharashtra,
India - 400058

Dear Sir,

Sub:- Buyback

This is to inform you that the file uploaded by you / your RTA for the above-mentioned purpose, has been successfully processed at **Central Depository Services (India) Limited**. The details of the same are as follows:

CA Seq. No.	ISIN	Type Of Security	Date Effected	No. of Records	No. of Securities
504007.002	Debit ISIN INE354A01013	Jenburkt Pharmaceuticals Limited # Equity Shares	10-Jan-2023	1	8830

Thanking you,

Yours faithfully,
For **Central Depository Services (India) Limited**

Vinifer T Kodia
Asst. Vice President – Operations

c.c Bigshare Services Private Limited

Digitally signed by VINIFER TEHMTON KODIA
Date: 2023.01.11 11:20:03 +05:30

Regd. Office : Marathon Futurex, Mafatlal Mill Compounds, A-Wing, 25th floor, N M Joshi
Marg, Lower Parel (East), Mumbai - 400013.

Phone: 91 - 22-2302-3333 • Fax: 91 - 22 - 2300 2035/2036. CIN: L67120MH1997PLC112443

Website : www.cdslindia.com